Answers are grounded in this paper and cite their sources.
Co-occurring genetic alterations in STK11/LKB1, TP53, and CDKN2A/B-the latter coupled with low TTF1 expression-define three major subgroups of KRAS-mutant lung adenocarcinoma with distinct biology, patterns of immune-system engagement, and therapeutic vulnerabilities.
No takes yet. Share an insight, caveat, or question.
Skoulidis et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: